Author(s): Martine Boetje | Daniel Bunout | Gladys Barrera | Maria Pia de la Maza | Laura Leiva | Sandra Hirsch
Journal: Ageing Research
ISSN 2036-7384
Volume: 2;
Issue: 1;
Start page: e7;
Date: 2011;
Original page
Keywords: statin | myopathy | functional capacity | muscle mass | socioeconomic status
ABSTRACT
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) may produce mild to severe myopathy. However, it is unclear if sarcopenia (decreased muscle mass and functional capacity) is also accentuated by the drugs. In a cross-sectional design, functional capacity (timed up and go, quadriceps- and hand grip strength) and lean body mass were compared between 71 low-dose statin users (
Journal: Ageing Research
ISSN 2036-7384
Volume: 2;
Issue: 1;
Start page: e7;
Date: 2011;
Original page
Keywords: statin | myopathy | functional capacity | muscle mass | socioeconomic status
ABSTRACT
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) may produce mild to severe myopathy. However, it is unclear if sarcopenia (decreased muscle mass and functional capacity) is also accentuated by the drugs. In a cross-sectional design, functional capacity (timed up and go, quadriceps- and hand grip strength) and lean body mass were compared between 71 low-dose statin users (
